CASES Insights Into Breast Cancer Central 2020

Perspectives on current treatment practices in the central region of the US regarding therapy of HR+, HER2+, and triple-negative advanced breast cancer. And insights on current treatment practice attitudes toward recently introduced and upcoming agents

Central – May 2, 2020
Purchase Report

Faculty Chair

Mark Pegram, MD

Stanford Women’s Cancer Center, Palo Alto, CA, USA

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

Insights on the following breast cancer therapies were obtained

  • HR+: fulvestrant, letrozole, AIs, CDK4/6 inhibitors, PI3K and mTOR inhibitors, HDAC inhibitors, chemotherapies
  • HER2+: trastuzumab (and potential biosimilars), lapatinib, pertuzumab, T-DM1, neratinib, AIs, mTOR inhibitors, chemotherapies
  • TNBC: PARP inhibitors, pembrolizumab, enzalutamide, antibody-drug conjugates (sacituzumab govitecan, GPNMB), immunotherapy, chemotherapies

GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT

  • A moderated virtual roundtable discussion focusing on treatment of metastatic breast cancer was held in May 2020
  • Disease state and data presentations were developed in conjunction with Mark Pegram, MD, a medical expert from Stanford Women’s Cancer Center
  • The group of advisors comprised 13 community oncologists from the central region of the USA
  • Data collection was accomplished through use of audience response system questioning and moderated discussion

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.